Osemitamab is under clinical development by Transcenta and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Osemitamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Osemitamab (TST-001) is under development for the treatment of solid tumor including gastric cancer, gastroesophageal junction cancer, metastatic adenocarcinoma of the pancreas, adenocarcinoma of the gastroesophageal junction, metastatic biliary tract cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, ovarian cancer, colon cancer, gallbladder cancer and lung cancer. The drug candidate is an humanized monoclonal antibody which acts by targeting claudin18.2. It is administered through intravenous route. It is based on Transcenta's Immune Tolerance Breaking Technology (IMTB) platform.
Transcenta (Transcenta Holding) that is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. The company is headquartered in Suzhou, Shanghai, China.
For a complete picture of Osemitamab’s drug-specific PTSR and LoA scores, buy the report here.